Nasdaq

Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell ...
Nasdaq

Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients ...

– 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA; 68 Percent Primary-Endpoint Complete Response Rate ...
Business Wire

Business Wire - Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy ...

The secondary endpoints include survival rates and change from baseline in HSCT-TMA laboratory markers. Consistent with the pre-specified statistical analysis plan for the trial, the primary and ...